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Assay are as shown (PPV = Pos, Predictive Value; NPV = Nag. Predictive 
Value): 
Cor¢ord~nt Discordant Sans. Spe¢. PPV NPV 
Resulm Resur~ 
(95.2%) 23 [4.B%) 97.2% 91.3% 9.4.2% 95.~ 
Using the McNemar test, we found that the cutoff or the cTnT Rapid Assay 
was not significantly different (p = 0.40) from the specified 0.2 ng/mL ES-300 
vatue for a hypothesis of 95"/,, confidenoe. 
Use of the cTnT Rapid Assay In Idage or risk stratification strategies is 
promising because it uses EDTA whole blood, requires only 20 rain, and has 
a O.R ng/mL cutoff that ¢oweietas well with the established quantitative ssay 
used in other studies. 
~ The Value of  Bedside Troponin T Testing in the 
Emergency Room for Risk Str~itlaation in 
Patients With Chest Pain After Discharge From 
Hospits l  
Bdtta U, Gotdmann. Chdstian W. Harem, Jan C. Schneider. Gescho M. VoB. 
Thomas Meinellz, Un/vers/fy Hospital Eppendoff, Dept. of Cardiol~, 
Hamburg, Germany 
The value of a newly developed bedside assay for trOponln T (l"nT) mea- 
surements to predict coronary heart disease was recently demonslra~ad. 
We investigated, whether early bedside lroponin T measurements in the 
emergency room are also useful for risk stratification in pts with suspected 
tschemio heart disease after discharge from hospital. We screened n = 236 
pts (male/female 141/95, age 63 4- 15) presenting to the emorge~'cy room 
for the mason of acute chest pain 7 + 5 hrs after onset of symptoms. Cardiac 
TnT was determined semi-quantitatively ad admission and after a six houm 
interval Pts. with at least one positive test result were considered TnT pos- 
itive. All pts were followed for one month after discharge from the hospital 
to record cardiac events (AMI, death) or the need for further interventions 
(coronary angloplasty: PTCA, bypass surgery: AGVB). 
Results: 1 month follow-ap aftsr discharge: 
TnT pos~thre TnT he.rive p value 
n~47 n = 18"Z 
I~ath e (1 ~P~) 2 (1%) <0.01 
AMI 12 (26%) 2 (1%) <0.01 
AC',/B 1 (2%) 2 (1%) n.s. 
PTGA 3 (13%) . . . .  9(S%) n.s. 
NI events occured after discharge from hospital. Cause of death in the 
TnT negative group in two pts. was stroke and cerebral neopl~m. Two pts. 
in the TnT negative group developed myocardial infarction after exclusion of 
AMI 1 month before. 
Condu~bn: The 0resent msuilS suggest that mp~d TnT meesumments 
in the emergency room may allow eady risk slretif~:~tion and prediction of 
cardiac events after discharge in pts with suspected coronary heart disease. 
~ L o w  Weight Heparin (I)altepadn) Molecular In the 
Management of Unstable Coronary Artery 
Disease (FRIC) 
W. Klein for the FRIC Study Group. Austria, Canada, Germany, Italy, 
Norway, The Netherlands, Spain. Unfted Kingdom, Unit~ Stetes 
Asp|fin and heparin reduce the risk of ischaemtc events including death and 
MI in unstable CAD, bUt reactivation may occur when hopadn Is discon- 
tinued. Low moleu-ular weight heparins (LWMH) have pharmacological nd 
phan~lkokinetlc prepares that may improve entithmmbeti~ therapy and at- 
low long-term tmatmanL The FRIO study 13 a multi-centre •al In patients 
with unstable CAD receiving aspirin and conventional antlanglnal trealment 
who were openlY randomized to LMWH (daltoparin) 120 IU/kg b.w. 12-houW 
~C or ]V-hapafln followed by SC heparin (APTT 1.5-2,0 X control) for 5-8 
days during hospitalization. In a long-term tmetmenl comparison, patients 
received eith:, dalteparin (7500 IU/day) or placebo SO for 40 days acoording 
to a double-blind random allocation at enW to the trial. The primary objective 
of the study was to determine the efficacy and safety of daltepadn In reduc- 
ing death, MI and recuwence of angina between day 6 and 45. Secandapj 
outcomes were death, MI, recurrent angina or revas~ularization during the 
~mndap/Oulcon'~z Daftapar/n Heparfn p 
(D.._a!m 5-8) % . . . . .  (n = 751 ) (.n -731) 
Reva~u~dz~t[on 5.2 5.8 0.48 
Oeath~ti/l:teeumsnt A gina/Revazcularlzallo n 13.0 12.5 0,99 
~ . o r ~ m  . . . . .  0 .3 . , .o  . .  
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hosp'dat phase. 1500 patients were recru/ted and the data from the I~osp~,~l 
phase are shown in the table. 
"/'he data show no d~erence In the incidence of ischaemi¢ events and 
in safety between the ~vo ffeatments in the hospital phase. Ccmpafisen of 
the I~imery outcomes between the two tmam~nt groups at day 45 will be 
presented. 
~ Braunwald Anginal Class as Risk Factor for the 
Oecummce o l  Early and Late Clinical Events 
Following Comne~ AngloplaMy (PTCA) for  
Unstable Angina Pectoris (UAP) 
Jean-Paul R. Herrman, Rein Meiked, Ke~h Fox 1, Patdck W. Sen'Ws on 
behaff of the HELVETICA investigators. 1The Un/vers//y of Edinburgh, 
Edinburgh, United Kingdom; Thoraxcentre, Erasmus Universe, Rotterdam, 
theNethedarx~ 
Background: Clinical events such as death, myocardial interc~on (MI), bail- 
out, bypass surgery (GABG) and re-PTGA hamper early and late outcome of 
PTCA. This ancillary study thvestigated the effect of the severity of UAP on 
eady and late adverse clin'¢at outcome (occumng within 4 or 210 dsylS). 
Methods: The studied population enrbled prospec~vely the HELVETICA 
study, in whk;h recombinant •rudin (HIq i.v. or Lv. + s.c. was compared to 
hepafin (Hap) tmatmenL Bfaunwald's classif'¢etion lEG) for UAP was used. 
~C I: New onset or accelerated AP, no rest pain. BC I1: AP at rest within the 
past month, BC Ill: AP at rest within the preceding 48 hours. 
Results: The table presents the percentage of patients experiendng early 
or late clinical events per Bmurmrald class and per tmathtont group or total 
pepulation. 
Eady events Late events 
Treatn~nt Hit Hir Hap Total H/r Hit Hap Total 
iv+sc iv iv+sc iv 
N - .'178 381 382 1141 378 381 382 1141 
BC I 3,6 8.9 4.6 5.8 24.5 90.8 22.9 27.4 
(N" 416) 
BC II 4-2 8.1 10.4 7,6 34.9 39.4 39.3 37.3 
(N " 489) 
8C II! t2.3 5.3 21.6 13,6 39,7 41.3 35.2 38.6 
(N-236) 
P 0.02 NS 0.00 0.00 0.04 NS NS 0,00 
(N? 416) . . . . .  
Con(fusion: Incroa~_ severity Of unstable angina results in an overall 
sig~ifican~ increased sk for the oocunenca of ea,'ty and Icte clinical events. 
~ Impsct of  Patient Delay and Thrombolytle 
Trealment on Mortal ity Among 5978 Patients With 
Acute Myoca~llal  Infar¢l lon 
MiChael OtteSen, Lars K~ber, Christian Torp-Pedersen. Department of 
CaraWay, C, ento~e University HoCk.  DenmarX 
Background: lime from onset of symptoms of acute myocardial infamtfon 
(AMI) until admission in ~ is extremely important, as the greatest 
dsk of death is within the first hours. Time from onset of symptoms until 
administration o1 thmmlytic therapy (Tt') is deten-dnsnt oi its efficiency in 
reducing morbidity and mo~lity. 
Nm: To assess the impact of paliont delay on short- and Iong-temq mort~ity 
following AML 
Methods: 6676 consecutive cases ot AM1 were adz~1ed in 27 centers 
in Oenmad~ from May 1990 to June 1992, Baseline cheractadstica, p l~nt 
delay and Ueetment was registered. Data on ~r~l@ were ~¢ed tn~ 
Oonish Ce~x'~I Fo~onal Register on the 15th July 1994. Patients were 
etmtified accoc~ig to dalw into threa groups I) deiay< 2 houm (n = 2039), 
2) delay 2-6 hours (n - 2049) and 3) delay > 6 hours (n = 1890). 
Results: In 5978 (89.5%) cases infom~tion on paUent debzy was mrsilable. 
Mean delay 9,1 houm and median delay 3.25 bourn, 2512 (42.0%) patients 
were mceivIn9 TI", Six d~y sun~'al rate was 95% in group 1,94% in group 2 
and 3 (N,~). The one, two and thrse year sundvat rates were 82%, 75% and 
70% In group 1, 79%, 72% and 66% th group 2, aed 73%, 67% and 60% 
~n group 3Lo < o.o~), sy camp~ pa~ie~s who received TT, to those who 
did not. it was shown that the difference between the three gmupa In suntival 
~es  en(y wes observed eatong i~llents who received T~. One, ~o  and 
threa year survlval ratss were 88%, 84% end 80% In group I, 84%, 79% and 
"/3% in ~oup 2, aad 81%, T/% and 73% th group 3 for those who n~mcl  
For thosa who dld not mseive TT, o~,  ~o and three ysar survival rates 
w~e 74%, 65% and 58% In greup l, 72%o S4% and S"i% in gm~ 2, and 
71%, 64% end 57% (n group 3, Them was slgnificanl dllterenoe in sunmra 
rates betwean the three groupa arrmng patients who rsceived TT {p < 0.01 ), 
but not when patients for various reasons were denied Tr. 
Conclusion: Patient delay In patients admitted alive with an AMI had no 
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impact on mortality, when the patient did not receive thmmbolytic treatment. 
Patients who received thrombolytic treatment had benefit of early admission 
and thrombelysis as long as three years pest-AML 
~ Clinical Charecfarletics Predictors of Mortality as 
in Poet-Myocardial infarction Patients 
R.T. van Domburg, J.W. Deckers, A.J. Azar, P.RM.M. van Bergen, 
J.J.C. Jonkar. Univers#y HoSl~ita/ Dijkzigt and Erasmus University 
Rotterdam, The Netherlands 
We investigated the relative contribution of variables from the history of the 
patient at admission and additional information obtained uring hospitaliza- 
tion in 3404 pest-myocardial infarction patients (80% male). Included were 
patients with at least two of the following criteria: persistent chestpain typical 
for MI, at least twice the normal enzyme fimif and ST-T changes on the 
electrocardiogram. Excluded were patients with indication for oral anticoag- 
ulant treatment, increased bleeding tendency, cardiomyopathy, anticipated 
revasculadsation, malignant disease, mental disorder and pregnancy. 
Patients were admitted from 1986 till 1992. After a median follow-up of 
3 years (0.5-6 years) 359 patients had died. In 77%, the cause of death 
was cardiovascular. Data on infarct size were not available. Multivariate Cox 
regression was performed on both history and hospitalization variables. 
HR and 95% CI History History + hospitalization 
Age/year 1.07 1.06--1.08 1.07 1.06-1.08 
Diabetes 1.39 1.01-1.91 
History of angina 1.33 1.04-1.71 
Previous infarction 1.68 1.26-2.23 1.62 1.22-2.15 
Hospitalization History + hospitalization 
Heartha'~JureJnhospJte] 2.71 1.97-3.72 2.05 1.80-2.80 
VTNF > 24 hour 1.50 0.90-2,48 1,57 0.97-2.55 
Thrombolysis 0.48 0.35-0.67 0.74 0.54--1.00 
Beta-blocker 0.60 0.48-0,76 0.69 0.55-0.63 
Prediction of outcome improved when additional information was added 
to the model. Relative simple clinical characteristics, as shown in the table, 
contributed significant in the prediction of mortality. 
These data illustrate the importance of an integrated approach to outcome 
prediction in pest-myocardial infarction patients and provide a minimum set 
of variables that should be included when the relative worth of additional 
prognostic tests is considered in these patients. 
I-~"(~"9.-9-0-'1 Left Ventrioular Functional Detsrminants o f  2 Yea r 
Mortality Following Acute Myocardial Infarction 
Conor F. Lundergan, Jonathan S. Reiner. Ailed M. Ross. George 
Washington Universi~, Washington, D.C. 
Numerous indices of global and regional left ventricular function have been 
used to stratify early or intermediate t rm mortality prognosis following acute 
myocardial infarction (AMI). In a large and unique population, the GUSTO-1 
Angiographlc Trial, 2 year mortality data is now complete with only 115/2431 
(4.7%) patients lost to follow-up. We determined the relative contribution of 
venfficulographic indices obtained within 5-7 days of the Index AMI to 2 
year mortality by multivariate logistic regression analysis in 1808 patients 
with complete anglogrophic and 2 year mortality data sets. Angiogrophlc 
variables included ejection fraction (El=), end systolic volume index (ESVI), 
end-diastolic volume index (EDVI), regional extent of infarction (# of chords) 
and regional infarct severity (SDIchord). Variables were entered into the mul- 
tivariate model in a stepwlsa manner eflective of their blolo"dc significance. 
EF, ESVI, EDVI, regional extent and severity of Infarctior, ,ere significant 
determinants of 2 year mortality by univariate analysis (all ~, < 0.0001). In- 
dependent determinants of 2 year mortality were: (RR = relative risk; CI = 
confidence limits) 
RR 95% CI 
EF (< 40, > 40) 2.8 (1.8,4,3) 
# Chords (< 16, • 16) 1.9 (1.3, 3.0) 
ES,,Vi (< 34, > 34) 1.8 (1.2, 2.7) 
Conclusions: 1. This prospective study illustrates the relative contribution 
of global and regional indices of ventricular function to long term mortality 
following AMI. 2, Global ventficular function and the extent of regional van- 
tricular dysfunction i  the infarct zone are each potent independent predictors 
of long term (2 year) prognosis in AML 
Angioplasty: Complications 
Wednesday, March 27, 1998, Noon--2:00 p.m. 
Orange County Convention Center, Hall E 
Presentation Hour: 1:00 p.m.--2:00 p.m. 
[ 1010-1091 Predictors and Late Sequelae of Distal 
Embolizetion In Patients With Cmetlne Klnsse 
Elevation Following Elective PTCA 
Thomas Q, Kong, Sheridan N. Meyero, Mlchele A, Parker, Michael D. EIliott, 
Charles J. Davldson, Northwestern University Medical School, Chicago, IL 
We have previously shown that distal embolizatton (DE) at PTCA frequently 
results in croatine kinase (CK) elevation (99% incidence). To identify predic- 
tors of distal embolization, anglographlc data from patients with CK elevation 
after elective PTCA using DCA, TEC, or balloon were evaluated. Logistic 
regression analysis was employed to determine device and lesion character- 
Istics as well as their interactions which were predictive of distal embelization. 
Results: Elective PTCA was performed on 503 lesions in 237 patients 
who developed CK elevation after PTCA (62 :E 11 yrs; 70% male; 2.1 :E 1.3 
lesions per patient). DE was observed following treatment of 75 lesions. 
Un.. ~adate DE No DE p Multivariate p 
TEc (%) 32 9 <0.00001 TEC O.O0t 
Thrombus (%) 32 10 <0.00001 DGA 0,006 
DCA (%) 31 11 <0.00001 Thrombus 0.0003 
Initial stenosis (~.) 91 ± 9 86 ± 13 <0.01 
Total occlusion (%) 15 7 < 0.04 
Init. TIMI flow < 3 (%) 40 24 <0,03 
Vein graft PTCA (%) 31 10 <0.00001 
At 3.5 -4- 2.3 years follow-up, cardiac death occurred in 15/69 (22=/0) of 
patients with vs. 19/168 (11%) without DE (p < 0.04). 
Conclusions: 1) The use of DCA or TEC is strongly associated with distal 
embolization. 2) Thrombus is the only angiographic lesion characteristic that 
is independently associated with DE. 3) DE is predictive of excessive late 
cardiac death. 
I 1010-1101 Vascal•r Access Site Complications During 
Angloplesty With Glycoprotein Ilbllla Receptor 
mhlbition In the IMPACT II Trial 
James Blankenship, Jeffrey Mandak, Frank Aguirre, Scott D. Berkowitz, 
lan GIIchrist, Khaltd Sheikh, John Griffin, Michael Mclvor, Jon Rasar, 
Bonnie Weiner, John George, David Tally, Gerald "rimmis, Michael Uncoff, 
James Tcheng, Robert Califl, Eric Topoi for the IMPACT II Investigators. 
Gelsinger Medical Center, Danviffe, PA 
Glycoprotein lib/Ilia receptor inhibition during coronary interventions lint) has 
been associated with excess vascular access site (VAS) complications. We 
assessed VAS complications from tot with a new glycoprotsin lib/ilia receptor 
inhibitor (Integrolin) in the IMPACT II trial. 4010 patients (pts) undergoing Int 
were randomized to placebo vs bolus/low dose 24 hour Infusion vs bolus/high 
dose 24 hour infusion of Integrolin. Heperin during Int was weight-adjusted 
and was stopped 4 hrs before sheaths were pulled. 
Results: Vascular surgical repair was rare (1"/o) and did not correlate with 
treatment, artedat sheath size, time to sheath removal, or use of a venous 
sheath. 79% of all moderate-severe bleeds occurred at the VAS. Moderote- 
severe VAS bleeding occurred in more Integrolin-treated pts (8,8% vs 5.3% 
placebo pts, p =, 0.0001), pts with venous sheath (8.4% vs 5.7=/0 no sheath, p 
= 0.002) and pts with sheath removed > 12 h (9.6% vs 5.6% sheath >_. 12 h, 
p ,= 0.0001). Procedural ACT was higher (398 ± 142 vs 388 + 185 seconds, 
p = 0,02) In modemmte-severo VAS bleed pts than in none/minor VAS bleed 
pts, A trend toward more rnodemta-severo VAS bleeding was observed with 
larger sheath size (p = 0,08). 
Conclusions: 1) Integrciin increases moderata-severo VAS bleeding. 2) 
VAS bleeding may be reduced by early sheath removal and avoiding venous 
sheaths. 3) Early sheath removal during inhibition of platelet aggregation by 
Integrciln is safe and may be a preferred strategy. 
11010-111 I Reuse of FrCA Catheters Is Not Associated With 
" Increased In-hospital Complications 
Kocn-Hou Mak, Mark J, Eisenberg, Sylvaln Plants, Bradley H, Strauss, 
Kdstopher L Aphead, Eric J. TopoL The Cleveland Clinic Foundation, 
Cleveland, OH 
Although catheter ouse may reduce cost, a recent prospective study in 693 
patients compared a center that rouses PTCA catheters with a center that 
uses only new catheters uggested that potential savings may be offset by 
increased in-hospital complications. To examine this issue, we roanalyzed 
